| 351 |
LENVACARE 4 |
LENVATINIB 4 MG |
CAPSULE |
BOTTLE |
AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROIDCARCINIMA, REFRACTORY TO RADIOACTIVE IODINE. AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR UNRESECTABLE HEPATOCELLULAR CARCINOMA WHO HAVE RECEIVED NO PRIOR SYSTEMIC THERAPY |
NULL |
BOTEN ELEMENTO PHARMA FACTORY |
BOTEN ELEMENTO PHARMA FACTORY |
LAOS |
CERTIFICATE RELEASED |
03 L 0850/21 |
20-FEB-2025 |
19-FEB-2030 |
View |
| 352 |
LORLACARE |
LORLATINIB 100 MG |
CAPSULE |
BOTTLE |
FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE-POSITIVE METASTATIC NON - SMALL CELL LUNG CANCER WHOSE DISEASE HAS PROGRESSED ON CRIZOTINIB AND AT LEAST ONE OTHER ALK INHIBITOR FOR METASTATIC DISEASE OR ALECTINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC OR CRITINIB AS THE FIRST ALK INHIBITOR THERAPY METASTATIC DISEASE |
NULL |
BOTEN ELEMENTO PHARMA FACTORY |
BOTEN ELEMENTO PHARMA FACTORY |
LAOS |
CERTIFICATE RELEASED |
03 L 0849/21 |
07-AUG-2024 |
06-AUG-2027 |
View |
| 353 |
LORLACARE |
LORLATINIB 25 MG |
CAPSULE |
BOTTLE |
FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE-POSITIVE METASTATIC NON - SMALL CELL LUNG CANCER WHOSE DISEASE HAS PROGRESSED ON CRIZOTINIB AND AT LEAST ONE OTHER ALK INHIBITOR FOR METASTATIC DISEASE OR ALECTINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC OR CRITINIB AS THE FIRST ALK INHIBITOR THERAPY METASTATIC DISEASE |
NULL |
BOTEN ELEMENTO PHARMA FACTORY |
BOTEN ELEMENTO PHARMA FACTORY |
LAOS |
CERTIFICATE RELEASED |
03 L 0848/21 |
22-AUG-2024 |
21-AUG-2027 |
View |
| 354 |
OSIMERFE |
OSIMERTINIB 80 MG |
TABLET |
BOTTLE |
TREATMENT OF NON SMALL CELL LUNG CANCER IN ADULT |
NULL |
BOTEN ELEMENTO PHARMA FACTORY |
BOTEN ELEMENTO PHARMA FACTORY |
LAOS |
CERTIFICATE RELEASED |
06 L 1120/24 |
07-AUG-2024 |
06-AUG-2027 |
View |
| 355 |
SELPERCARE |
SELPERCATINIB 40 MG |
CAPSULE |
BOTTLE |
FOR THREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON SMALL CELL LUNG CANCER |
NULL |
BOTEN ELEMENTO PHARMA FACTORY |
BOTEN ELEMENTO PHARMA FACTORY |
LAOS |
CERTIFICATE RELEASED |
02 L 0899/22 |
31-MAR-2025 |
30-MAR-2030 |
View |
| 356 |
SEMAGCARE |
SEMAGLUTIDE 14 MG |
TABLET |
BOTTLE AND BLISTERPACK |
AS AN ADJUNCT TO DIET AND EXCERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS |
NULL |
BOTEN ELEMENTO PHARMA FACTORY |
BOTEN ELEMENTO PHARMA FACTORY |
LAO PDR |
CERTIFICATE RELEASED |
10 L 1213/24 |
04-Oct-2024 |
03-Oct-2029 |
View |
| 357 |
SIALIS |
TADALAFIL 10 MG |
TABLET |
BLISTERPACK |
USE FOR ERECTILE DYSFUNCTION AND BENIGN PROSTATIC HYPERPLASIA |
NULL |
BOTEN ELEMENTO PHARMA FACTORY |
BOTEN ELEMENTO PHARMA FACTORY |
LAO PDR |
CERTIFICATE RELEASED |
03 L 0857/21 |
06-Dec-2024 |
05-Dec-2029 |
View |
| 358 |
SOTORCARE |
SOTORASIB 120 MG |
TABLET |
BOTTLE |
TREATMENT OF NON SMALL CELL LUNG CANCER IN ADULT |
NULL |
BOTEN ELEMENTO PHARMA FACTORY |
BOTEN ELEMENTO PHARMA FACTORY |
LAOS |
CERTIFICATE RELEASED |
03 L 0903/22 |
31-MAR-2025 |
30-MAR-2030 |
View |
| 359 |
SUPER SIALIS |
TADALAFIL 20 MG, DAPOXETINE 30 MG |
TABLET |
BOTTLE AND BLISTERPACK |
FOR USE AS NEEDED FOR ERECTILE DYSFUNCTION AND PREMATURE EJACULATION IN ADULT MEN AGED 18-64 |
NULL |
BOTEN ELEMENTO PHARMA FACTORY |
BOTEN ELEMENTO PHARMA FACTORY |
LAO PDR |
CERTIFICATE RELEASED |
03 L 0854/21 |
16-OCT-2024 |
15-OCT-2027 |
View |
| 360 |
AMOXIN - CBF |
AMOXICILLIN SODIUM EQ. TO AMOXICILLIN 1G |
POWDER FOR SOLUTION FOR INJECTION |
VIAL |
UPPER RESPIRATORY TRACT INFECTIONS, OTITIS MEDIA, ACUTE AN DBRONCHIAL BRONCHITIS, CHRONIC BRONCHIAL SEPSIS, CYSTITIS, URETHRITIS, PYELONEPHRITIS, BACTERIURIA IN PREGNANCY, GYNAECOLOGICAL INFECTION, GONORRHEA, SEPTICAEMIA, TYPHOID AND PARATHYPHOID FEVER, SKIN AND SOFT TISSUE INFECTION… |
NULL |
CBF PHARMA CO.,LTD |
NORTH CHINA PHARMACEUTICAL CO., LTD |
CHINA |
CERTIFICATE RELEASED |
11 I 3925/13 |
26-SEP-2022 |
25-SEP-2025 |
View |
